DDR on DTC: Onglyza

Share this article:
It's no secret that obesity and its nasty spawn, type 2 diabetes, have reached epic proportions. Unfortunately both conditions are difficult to treat due to complicated and individualized issues in every patient, not to mention the emotional components tied to eating, sharing mealtimes, and so on.

Now Bristol-Myers Squibb and AstraZeneca have teamed up to help T2s gain some control over their blood sugar “spikes” with Onglyza—and they are effectively using DTC to help educate patients and caregivers about it, too. The campaign uses TV, print and online tactics to reach an older-skewing audience—and likely T2 candidates. One of the best aspects of the advertising is the casting. They look like people we know and love who are just trying to deal with the complexities of their condition. And we are relieved that Onglyza can help them solve their problems.

This is a category that truly challenges agency creatives because the disease is so complicated and the treatment so daunting that it's hard to generate a single, key selling idea. But BMS and AZ have succeeded in conveying that there is something new that can help T2s in their struggle to better control their blood sugar levels. They have done this with straightforward graphs and simple language.

All good. But the Onglyza ads just need to pop a bit more and look less like every other DTC ad. While the campaign is educational and well cast and leverages a memorable graphic, it could be “kicked up a notch” to make it more memorable and drive action.

Deborah Dick-Rath is SVP, healthcare practice leader, at FactorTG. Contact:
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?